Sanara MedTech Inc. (SMTI) stock intrinsic value fair value estimate & owner earnings analysis

Sanara MedTech sells surgical wound-care and bone-fusion products to operating rooms and surgery centers in the United States through independent distributors. Its lead products are CellerateRX Surgical powder (a hydrolyzed collagen) and BIASURGE; soft tissue repair products were $91.3 million of 2025 revenue and bone fusion products about $11.8 million. Revenue has grown every year since 2019 and reached $103.1 million in 2025 (up 19%) at a gross margin near 93%. Pending merger. On July 29, 2026 Sanara agreed to be acquired by MiMedx Group for $33.00 in cash plus 0.4735 MiMedx shares per Sanara share. Sanara shareholders approved the deal on September 30, 2026; the U.S. antitrust waiting period was restarted at MiMedx's election and is scheduled to end October 15, 2026, and the agreement's outside date is July 29, 2027. If the merger closes, holders receive that consideration. Everything below values Sanara as a standalone business and does not assume the merger happens or fails. The merger terms come from the companies' announcements and SEC communications rather than the annual report. What changed since our last analysis. Our earlier figures (bear $3.24, base $15.09, bull $31.56) were built on a different basis and are not comparable. In the business itself: the Tissue Health Plus wound-care services venture was shut down in the third quarter of 2025 (a $37.2 million loss for 2025 including a $26.5 million write-off, after an $8.0 million loss in 2024); quarterly revenue growth slowed from 18.6% in the first quarter of 2026 to 9.0% in the second; cash interest on the term loan doubled to $3.05 million in the first half of 2026; and the merger agreement was signed. How we measure earnings. Owner earnings are cash from operations, less swings in working capital, less stock compensation (a real cost, $5.2 million in 2025), less the capital spending needed to stay in business. On the reported figures this is -$0.42 per share in 2024 and +$0.06 in 2025, but those years include Tissue Health Plus, which consumed roughly $7 million of cash in 2024 and $9 million in 2025 (derived from the company's discontinued-operations note), and $4.4 million of 2025 capital spending was a software platform for that venture, which we treat as discretionary growth rather than upkeep. Because we value the business before its lenders and then subtract the debt, we also add back cash interest. Without Tissue Health Plus, the surgical business produced about $5.8 million ($0.68 per share) in 2024, $13.3 million ($1.54) in 2025, and in the first half of 2026 an operating profit of $4.4 million that annualizes to about $11.7 million ($1.34). We anchor on $11.7 million a year, the middle of those three observations. Earlier years describe a $6 million-revenue company or the loss-making build-out years and are not used. Cash from operations was slightly negative (-$0.4 million) in the first half of 2026 even though operating profit was positive; the swing in working capital could not be fully reconciled from the interim data, and the most likely cause is payment of year-end bonus and commission accruals (which grew $3.1 million in 2024 and $2.1 million in 2025). Trailing actual growth in this cash flow was +127% in 2025 (from $0.68 to $1.54 per share, as Tissue Health Plus costs fell out of the picture and margins widened); our base case assumes +7% in the first year, below that trailing figure and below first-half revenue growth of 13.6%. Cash taxes are currently near zero; the company reported about $57.5 million of loss carryforwards at the end of 2024. We let them shelter earnings for roughly six years in the base case and tax earnings at 25% afterwards. What the company owes. The main debt is a term loan from CRG: $42.75 million borrowed plus $3.04 million of deferred interest added to principal, and a 7% exit fee (about $3.0 million), all due March 30, 2029. It carries 13.25% interest (8% in cash, 5.25% deferrable) and is secured by liens on substantially all assets including intellectual property. Covenants require at least $3.0 million of liquidity and annual revenue of at least $85 million in 2026, $95 million in 2027 and $105 million in every year from 2028; revenue for the twelve months to June 30, 2026 was about $109.8 million, so the 2028 minimum leaves little room. Because the loan carries 13.25% interest through March 2029, we count it, interest and exit fee included, at about $54.9 million rather than its $46.5 million balance-sheet value. Cash was $15.4 million at June 30, 2026; we treat $12.4 million of it as spare after the $3.0 million liquidity requirement. About 8.7 million diluted shares are outstanding. Base case: $10.96 per share. Revenue growth keeps slowing the way it has (7% in the first year, then fading by 30% a year to under 1% by year ten), with cash margins unchanged. Growth is credited only as the continuation of the distributor-network expansion that has produced revenue growth every year since 2019, including 2020, and only at rates below recent actuals. After year ten the earning power is held flat for five years and then fades to zero over fifteen more, resting on the recurring, high-margin sales of the existing products; no new products are credited. The business is worth about $138.2 million; it owes about $54.9 million; with $12.4 million of spare cash the difference is $95.7 million, or $10.96 per share. Left out: margin expansion (margins are already 93% gross), any sales from the OsStic bone-void filler licensed from BMI (no royalties had been paid as of year-end 2025; Sanara paid $8.3 million for a minority stake in BMI in 2025), new acquisitions, and any value for the minority investments. Bull case: $15.75 per share. First-year growth of 10% (first-half growth was 13.6%) fading by 15% a year, and earning power held flat for ten years after year ten before fading over ten more. The business is worth about $180.0 million and owes about $54.9 million; with $12.4 million of spare cash that leaves $137.5 million, or $15.75 per share. Bear case: $0.27 per share. Revenue stalls near $112 million for a year, then suffers a shutdown-style year like spring 2020, when hospitals postponed elective surgery: revenue falls 15% to $95 million and half of the lost revenue comes straight out of cash flow, then recovers only to $107 million. Management repeats its capital-allocation record (Tissue Health Plus, then the BMI investment) with another $5 million wasted. Revenue below the $105 million minimum for 2028 puts the loan in default (the contract adds 4% interest), and the March 2029 maturity must be refinanced at around 15%, close to the current loan's all-in cost once fees are included. After year ten earning power fades to zero over ten years. The business is worth about $66.5 million; its lenders are owed about $76.5 million once the higher interest is counted; with $12.4 million of spare cash that leaves $2.4 million, or $0.27 per share. In this case cash flow falls short of the interest bill in two of the first three years (the spare cash covers the gap) and shareholders are left with almost nothing. Testing the case. The anchor was checked against the first-half 2026 operating profit of $4.4 million on $55.9 million of revenue, which supports it; the cost of the loan was checked against $3.05 million of cash interest paid in the first half (about 13.3% a year on $45.8 million), which matches the contract; the growth path was checked against the quarterly slowdown, which is why it fades. If the true cash flow is 20% lower ($9.4 million) and never grows, the shares are worth about $6.03, and if it also fades to zero over ten years after year ten, about $4.02. Margin-of-safety price: $4.00 (applies if the merger is terminated and Sanara continues alone). We are moderately sure of the earnings level: the surgical business is clearly profitable and gross margins are stable, but we have only two full years (2024 and 2025) plus one half-year of figures without the venture, and those are reconstructed from the company's disclosures rather than reported. The worst plausible outcome is a revenue decline that breaches the 2028 covenant with a lender holding liens on everything, followed by a refinancing the business may not be able to carry; debt of about $49 million due in March 2029 is more than four times annual cash flow, and equity could be mostly lost. The company's recent new ventures, Tissue Health Plus and the BMI investment, have not produced returns so far. If we are wrong about the two things most likely to be wrong, the earnings level and growth, the shares are still worth roughly $6 (earnings 20% lower, no growth). The price assumes a holding period of about three years, until the loan is refinanced and the revenue minimums are cleared; the company pays no dividend, although after interest it keeps roughly $0.70 per share a year of cash in the base case. From $4.00, the lower-earnings, no-growth case implies roughly 20% a year over three years, and the base case implies considerably more; that is why the margin-of-safety price is $4.00 and not higher.